CHMP Recommends Approval of Praluent(R) (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease

TARRYTOWN, N.Y. and PARIS, Feb. 4, 2019 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has a... Biopharmaceuticals, Cardiology, Regulatory Regeneron Pharmaceuticals, Sanofi, Praluent, alirocumab, ASCVD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news